Compare Lamb Weston Holdings Inc (LW) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lamb Weston Holdings Inc vs Nuwellis Inc — how do they compare? Lamb Weston Holdings Inc trades at $49.24 (market cap $6.81B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: Lamb Weston Holdings Inc is far larger — about 3095.5× Nuwellis Inc's market cap, and Lamb Weston Holdings Inc pays a 3.07% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lamb Weston Holdings Inc for 66 Days and Nuwellis Inc for 26 Days on average.
| LW | NUWE | |
|---|---|---|
Market Cap | $6.81B | $2.20M |
Volume | 4,638,686 | 121,544 |
Sector | Consumer Staples | Health |
52-Week High | $66.57 | $146.65 |
52-Week Low | $38.48 | $0.68 |
Typical Hold Time | 66 Days | 26 Days |
Enterprise Value | $10.61B | -$1.52M |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lamb Weston (LW) trades at $48.09, up 0.38% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 14.17% ROE and trades at a P/E of 26.28. Recent news highlights cost savings exceeding $100 million and positive analyst sentiment for upcoming earnings. Support is firm at $48, aligning with the current price, while resistance sits at $49 and $50.
The outlook is cautiously optimistic given earnings momentum and analyst consensus, but risks include margin pressure from rising costs and competitive threats. The consensus price target of $53.71 suggests upside potential, though net income decline from $1.0B in 2023 to $357M in 2025 warrants monitoring operational efficiency.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
